Post

New research · Ophthalmology
Ocular immunology and inflammation · 4d
Cohort studyOcular immunology and inflammation · 2026

Efficacy of PAUL Glaucoma Implant® for Refractory Uveitic Glaucoma.

Samy Si Larbi, Bahram Bodaghi, Valérie Touitou … Agathe Vest
Read paper
OphthalmologyCohort study

Paul Glaucoma Implant markedly lowered eye pressure in refractory uveitic glaucoma at 2 years.

Efficacy of PAUL Glaucoma Implant® for Refractory Uveitic Glaucoma.

Samy Si Larbi … Agathe Vest
Ocular immunology and inflammation · 2026
Purpose

Evaluate the mid-term efficacy and safety of Paul Glaucoma Implant (Paul Glaucoma Implant) in patients with refractory uveitic glaucoma (refractory uveitic glaucoma).

Methods

Aged 18 years or older with refractory uveitic glaucoma and uncontrolled intraocular pressure (IOP) who underwent Paul Glaucoma Implant implantation between November 2021 and January 2025 at a tertiary uveitis center were included.

n = 25 eyes
Results

eye pressure was much lower after surgery, easing strain on the eye

72%
Before
87.5%
After
More results

Mean preoperative IOP was 25.5 ± 7.7 mmHg with 3.5 ± 1.1 medications.

Complete success decreased from 28% at 6 months to 12.5% at 24 months, while qualified success increased from 72% to 87.5%.

Visual field mean deviation remained stable (mean change -0.79 dB; p = 0.21).

More results

Surgical reintervention was required in 2 eyes (8%).

“
Conclusion · 1 of 2

Paul Glaucoma Implant provided sustained IOP reduction with a favorable safety profile in a refractory uveitic glaucoma population.

Conclusion · 2 of 2

These findings support the Paul Glaucoma Implant as a valuable surgical option in UG, although larger multicenter comparative studies are needed.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving